UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
State of |
||
(State or Other Jurisdiction | (Commission | (IRS Employer |
of Incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered |
||
* |
* Not for trading; only in connection with the registration of American Depositary Shares.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Exhibit Number
|
Exhibit Description
|
|
CHEMOMAB THERAPEUTICS LTD.
|
|
|
|
|
|
|
Date: November 14, 2022
|
By:
|
/s/ Donald Marvin
|
|
|
|
Name: Donald Marvin
Title: Executive V.P., Chief Financial Officer and
Chief Operating Officer
|
|
![]() |
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations,
Strategic Communications
Phone: +1-917-355-9234
barbara@chemomab.com
|
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com
|
GVEE-'/;^:QN%8D'<1QAAZ5GZM
M\;H].\-:=)%:P7&MW5N)98E)$4&>F> +OAHR;C9ZQ;W,?G1Q.
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M;P'H7A.R2*SLXY+G'[RZE0-(Y^O8>PKE.G2A"'M*OR02G)RY8G+/\ &/QU=/YL,L2)G[L5J"/US6KHWQZURUF5-8L;
M:\ASAFB!CD']/TKZ AL[6WB$4%M#%&!@(B!0/P%
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end
85 UN]OF&-Q4*.9:%-'E*5K3./N5<,7]F.!^OO'N3X*8SRR)48^Q&3
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MD+1W.T_Q]W2=8KL)($"K'FZT&/9DUQ%!I-E/+.>*4,/(]1ILD'I^@H55*"
MDQ2BQ)FOCFIZ-96A-)BHXK<&JJ*GJ8J>IBIZS51%EM[)JN@=5/&^@:KH:ZJB
MKZF*?C-5D:5WLBKZ!U5<-4450_;UB4SQ)ON/V@J42A%I5&/T4$CM.#6DS8DZ
ME Z4U(:$OC+H?NLA.51WVIV)F.73T??L.)]82L\S
M5>+3O\:#W?'.X/'V]F!W\GCKUIC;O$WRJ7L4]5'DD_>_U_=:KF#\]CQITY9'
MN\SJ#YZN*M\;?O5V\Q^IW6U ZH ''OY)>+=E=O2KP\.Q#O5AK\Z#&$X5"'HNGCY)Y
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M0"["LN(N<'B3S;I>R%FS_X*/:"0/;Y9-P$ Q$!7>(1+JYDB3B[@)MD$N"N2<,
U(Y0XA"/(,FZ^UIAK/X&
M2[(7L(72IIG!NREY;H3?T94;#^*-